Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis

Murphy, S. D. in Toxicology: The Basic Science of Poisons(eds Doull, J., Klassen, C. & Amdur, M.) 357–408 (Macmillan, New York, (1980)).

Tafuri, J. & Roberts, J. Organophosphate poisoning. Ann. Emerg. Med. 16, 193–202 (1987).

Smolen, A., Eckerson, H. W., Gan, K. N., Hailat, N. & La Du, B. N. Characteristics of the genetically determined allozymic forms of human serum paraoxonase/arylesterase. Drug Metab. Dispos. 19, 107–112 (1991).

Mackness, M. I., Arrol, S. & Durrington, P. N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 286, 152–154 (1991).

Watson, A. D. et al. Protective effect of HDL associated paraoxonase-inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96, 2882–2891 (1995).

Shih, D. M. et al. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J. Clin. Invest. 97, 1630–1639 (1996).

Mackness, M. I., Mackness, B., Durrington, P. N., Connelly, P. W. & Hegele, R. A. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr. Opin Lipidol. 7, 69–76 (1996).

Heinecke, J. W. & Lusis, A. J. Paraoxonase-gene polymorphisms associated with coronary heart disease: Support for the oxidative damage hypothesis? Am. J. Hum. Genet. 62, 20–24 ((1998)).

Costa, L. G. et al. Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats. Tox. Appl. Pharmac. 103, 66–76 (1990).

Li, W.-F., Costa, L. G. & Furlong, C. E. Serum paraoxonase status: a major factor in determining resistance to organophosphates. J. Tox. Envir. Hlth 40, 337–346 (1993).

Li, W.-F., Costa, L. G. & Furlong, C. E. Paraoxonase protects against chlorpyrifos toxicity in mice. Tox. Lett. 76, 219–226 (1995).

Humbert, R. et al. The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genet. 3, 73–76 (1993).

Davies, H. G. et al. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nature Genet. 14, 334–336 (1996).

Navab, M. et al. Monocyte transmigration induced by modification of low density lipoprotein in coculture of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J. Clin. Invest. 88, 2039–2046 (1991).

Navab, M. et al. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J. Clin. Invest. 99, 2005–2019 (1997).

Watson, A. D. et al. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J. Clin. Invest. 95, 774–782 (1995).

Mehrabian, M. et al. Influence of the apoA-II gene locus on HDL levels and fatty streak development in mice. Arterioscler. Thromb. 13, 1–10 (1993).